Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
On/Off study of missed daily doses in stable ADHD patients receiving atomoxetine or OROS methylphenidate
2009-011426-33Phase 4Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of atomoxetine and methylphenidate in attention deficit hyperactivity disorder (ADHD) (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: DPREMB-R subscale scores and DPREMB-R total score comparison on on versus off days. Started Aug 2009; status: terminated.
02
Drugs
atomoxetinemethylphenidate
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on 2009-011426-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011426-33.